Biocon Ltd inaugurated its first US manufacturing facility in Cranbury, New Jersey.
The plant is operated by its wholly-owned subsidiary Biocon Generics Inc. (BGI).
Biocon acquired the Oral Solid Dosage (OSD) facility from Eywa Pharma Inc. in 2023 and invested over USD 30 million to upgrade it.
Biocon Inaugurates First Manufacturing Facility in US
The company's wholly-owned subsidiary, Biocon Generics Inc. (BGI), operates the plant
Biocon
Summary
Advertisement
Biocon Ltd on Thursday said it has inaugurated its first manufacturing facility in the US, located in Cranbury, New Jersey.
The company's wholly-owned subsidiary, Biocon Generics Inc. (BGI), operates the plant.
Biocon acquired the Oral Solid Dosage (OSD) facility from Eywa Pharma Inc in 2023 and has since invested over USD 30 million to establish a plant with an annual production capacity of 2 billion tablets.
A few products have already been commercialised from the site, with several more in the pipeline, the Bengaluru-based firm said in a statement.
This investment helps Biocon diversify its manufacturing base, strengthen its supply chain and accelerate the expansion of its global footprint, it added.
"Biocon's first USFDA-approved formulations facility in New Jersey marks a new chapter in our journey of global expansion," Kiran Mazumdar-Shaw, Chairperson of Biocon Group, said.
The facility reflects the company's long-term commitment to deeper engagement with healthcare providers, innovators, and communities to build a healthier and equitable future, she added.
Advertisement
Show comments